HUTCHMED (China) Limited
HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastriā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$11.54
Price+3.68%
$0.41
1Y
Price
Market Cap
$2.013b
Mid
Price/Earnings 3y Avg5y Avg
4.3x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-10.5%
EBITDA Margin+0.7%
Net Profit Margin+1.2%
Free Cash Flow Margin-10.5%
EBITDA Margin+0.7%
Net Profit Margin+1.2%
Free Cash Flow MarginRevenue
$549.963m
-13.0%
1y CAGR+19.6%
3y CAGR+19.6%
5y CAGREarnings
$458.117m
+1111.0%
1y CAGR+392.1%
3y CAGR+272.8%
5y CAGREPS
$2.60
+1081.8%
1y CAGR+382.1%
3y CAGR+268.6%
5y CAGRBook Value
$1.251b
$1.753b
Assets$501.837m
Liabilities$97.893m
DebtDebt to Assets
5.6%
-3.8x
Debt to EBITDAFree Cash Flow
-$79.013m
-352.0%
1y CAGR-100.1%
3y CAGR-84.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company